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Abstract
DICER1 syndrome is a rare genetic disorder that predisposes to a wide spectrum of tumors. Developing surveillance proto-
cols for this syndrome is challenging because uncertainty exists about the clinical efficacy of surveillance, and appraisal of 
potential benefits and harms vary. In addition, there is increasing evidence that germline DICER1 pathogenic variants are 
associated with lower penetrance for cancer than previously assumed. To address these issues and to harmonize DICER1 
syndrome surveillance programs within Europe, the Host Genome Working Group of the European branch of the International 
Society of Pediatric Oncology (SIOPE HGWG) and Clinical Guideline Working Group of the CanGene-CanVar project in 
the United Kingdom reviewed current surveillance strategies and evaluated additional relevant literature. Consensus was 
achieved for a new surveillance protocol and information leaflet that informs patients about potential symptoms of DICER1-
associated tumors. The surveillance protocol comprises a minimum program and an extended version for consideration. The 
key recommendations of the minimum program are: annual clinical examination from birth to age 20 years, six-monthly 
chest X-ray and renal ultrasound from birth to age 6 years, and thyroid ultrasound every 3 years from age 8 to age 40 years. 
The surveillance program for consideration comprises additional surveillance procedures, and recommendations for DICER1 
pathogenic variant carriers outside the ages of the surveillance interval. Patients have to be supported in choosing the sur-
veillance program that best meets their needs. Prospective evaluation of the efficacy and patient perspectives of proposed 
surveillance recommendations is required to expand the evidence base for DICER1 surveillance protocols.
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Introduction
DICER1 syndrome is an autosomal dominant hereditary 
tumor predisposition syndrome that predisposes individu-
als to a variety of tumors, both benign and malignant [1, 2]. 
In 2009, disease-associated variants in the DICER1 gene 
were first described in families with multiple cases of pleu-
ropulmonary blastoma (PPB) [2]. Over time, numerous other 
manifestations have been associated with pathogenic ger-
mline variants in DICER1, including lung cysts, multinodu-
lar goiter, thyroid cancer, ovarian sex-cord stromal tumors, 
and cystic nephroma [1, 3–5]. Less commonly described 
manifestations in individuals with DICER1 syndrome 
include nasal chondromesenchymal hamartoma (NCMH), 
ciliary body medulloepithelioma (CBME), Wilms tumors, 
primary brain tumors, mesenchymal hamartoma of the liver, 
and sarcomas of various sites [1, 6–11]. The majority of 
tumors occur in infancy, childhood, and adolescence [12]. 
Macrocephaly is one of the few non-neoplastic features of 
DICER1 syndrome, which may also include retinal and 
structural renal abnormalities [10, 13, 14]. Possibly addi-
tional tumors or non-neoplastic features will be linked to 
DICER1 syndrome in the future.
In 2018, two independent groups proposed DICER1 syn-
drome surveillance protocols [15, 16]. Developing surveil-
lance protocols for DICER1 syndrome is challenging, not 
least due to uncertainty about the efficacy of surveillance 
for individuals with germline pathogenic DICER1 variants. 
Proposed surveillance protocols aim to reduce DICER1-
associated morbidity and mortality through early detection 
of tumors by imaging of several organs. However, the clini-
cal utility of these protocols remains to be validated [15–18]. 
The natural history (i.e., rate of malignant transformation) 
and growth rate of most DICER1-associated tumors has not 
yet been investigated [1, 19]. Another challenge in develop-
ing surveillance protocols is the potential harm associated 
with surveillance. Potential harms in DICER1 syndrome sur-
veillance protocols include overtreatment (e.g., unnecessary 
surgery for asymptomatic benign cysts detected on surveil-
lance), need for sedation in young children during imaging 
procedures, radiation exposure and psychosocial burden 
of repeated investigations and false-positive findings [20]. 
Given these potential harms, the question has been raised 
whether less invasive and less frequent surveillance regimes 
are reasonable. This issue has grown in importance in light 
of two recent findings. Firstly, approximately 95% of non-
index case individuals with germline pathogenic DICER1 
variants did not develop a tumor by age 10 years [12]. Sec-
ondly, germline DICER1 pathogenic variants may be more 
common in the general population than previously thought, 
reflecting a lower penetrance than previously assumed [19]. 
The current incidence of loss-of-function (LOF) variants in 
the gnomAD data set (71,702 genomes, accessed 23/10/20) 
is 1:5121 [21].
To address these issues, the Host Genome Working Group 
of the European branch of the International Society of Pedi-
atric Oncology (SIOPE HGWG) organized a meeting during 
which current surveillance protocols for DICER1 syndrome 
were reviewed and new surveillance recommendations were 
proposed. In addition, the Clinical Guideline Working Group 
of the CanGene-CanVar project in the United Kingdom was 
invited as a collaborator in the guideline development pro-
cess to harmonize surveillance programs within Europe. The 
joint recommendations, which both overlap and incorporate 
modifications compared to previous protocols, are presented 
and explained in this report.
Methods
In January 2020, the SIOPE HGWG met in Hannover, Ger-
many, to reassess current surveillance strategies for DICER1 
pathogenic variant carriers. Eighteen professionals from ten 
countries were present, including clinical geneticists and 
pediatric oncologists.
Prior to this meeting, a literature review was performed 
to identify articles on surveillance in DICER1 syndrome. 
The DICER1 syndrome surveillance protocol proposed by 
Schultz and colleagues was selected as key publication for 
discussion [16]. SIOPE HGWG members were surveyed for 
their opinions on these surveillance recommendations and 
were asked about their current practice and experiences. Sur-
veillance recommendations were draft based on the survey 
responses and expert discussions during the SIOPE HGWG 
meeting.
Following this meeting, experts in specific fields (e.g., 
endocrinology, pathology, radiology, and gynecology) 
were consulted for their input and the literature search was 
extended to identify additional relevant articles. A Pub-
Med search was conducted using the keywords “DICER1” 
[title/abstract] and “humans”[MeSH Terms] in combination 
with the keywords “screening” [title/abstract] OR “surveil-
lance” [title/abstract] OR “incidence”[title/abstract] OR 
“penetrance”[title/abstract] OR synonyms for the various 
DICER1-associated tumors (Supplemental Table 1). Articles 
written in English were included and there was no data limit. 
In total, 225 articles were found. Articles were included if 
they contained any data on the incidence, penetrance, or 
surveillance of DICER1-associated tumors. In addition, the 
CanGene-CanVar group in the United Kingdom was invited 
as a partner in the guideline development process. Similar to 
the SIOPE HGWG, the CanGene-CanVar Clinical Guideline 
Working Group aimed to develop new DICER1 syndrome 
surveillance protocols. To harmonize surveillance programs 
within Europe, it was appropriate to write joint guidance. 
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Revised protocols were assessed by all participants of the 
SIOPE HGWG meeting and members of the CanGene-Can-
Var group to ensure consensus. In addition, patient repre-
sentatives (n = 7) from the UK, Denmark, Switzerland, Ger-
many, and the Netherlands were consulted for their opinion 
on the comprehensibility of the information leaflet.
For evidence grading we used a scale that was introduced 
in the ERN GENTURIS Cancer Surveillance Guideline for 
individuals with PTEN hamartoma tumor syndrome: (i) 
strong evidence: consistent evidence and new evidence 
unlikely to change recommendation and expert consen-
sus; (ii) moderate evidence: expert consensus or majority 
decision but with inconsistent evidence or significant new 
evidence expected and (iii) weak evidence: inconsistent evi-
dence and limited expert agreement [22].
Results
The SIOPE HGWG and CanGene-CanVar propose new sur-
veillance recommendations for DICER1 pathogenic variant 
carriers, summarized in a surveillance protocol (Table 1) 
and a patient information leaflet (Fig. 1). The aim of the 
information leaflet is to inform patients, parents/guardians, 
and general practitioners about possible signs and symptoms 
of DICER1-associated tumors in order to reduce diagnos-
tic delay. This leaflet also comprises rare DICER1-associ-
ated tumors, like nasal chondromesenchymal hamartoma 
(NCMH) and primary brain tumors, for which we do not 
recommend standardized surveillance.
The surveillance protocol comprises a minimum pro-
gram as well as an extended version for consideration. 
The minimum program contains surveillance procedures 
(i.e., clinical examination and imaging-based surveil-
lance) for which the SIOPE HGWG and CanGene-Can-
Var assume that the benefits of surveillance outweigh the 
potential harms. The minimum program recommendations 
are based on expert consensus or majority decision but 
with inconsistent evidence or significant new evidence 
expected, except for annual neck palpation which is based 
on inconsistent evidence and limited expert agreement. 
We recommend annual clinical review from birth to age 
20 for possible signs and symptoms of DICER1-associated 
tumors (described in the information leaflet) and contin-
ued education and updates on proper vigilance. Annual 
physical examination should preferably be performed by 
a ‘key’ clinician who is also responsible for arranging and 
reviewing imaging-based surveillance to ensure appropri-
ate follow-up. We suggest that surveillance is provided and 
coordinated by pediatric oncologists in DICER1 patho-
genic variant carriers from birth to age 8 years, because 
of the broad spectrum of childhood tumors that can occur 
in this time period. Patients older than age 8 years can be 
seen by (pediatric) endocrinologists since the minimum 
surveillance program from this age onwards comprises 
only thyroid surveillance. Given the rarity of DICER1 
Table 1  SIOPE HGWG and CanGene-CanVar surveillance protocol for DICER1 pathogenic variant carriers
SIOPE HGWG Host Genome Working Group of the European branch of the International Society of Pediatric Oncology, US ultrasound, CT 
computed tomography
a For pregnant women whose fetuses are prenatally diagnosed with a pathogenic germline DICER1 variant or are at risk to be affected (i.e., 50% 
chance of inheriting a germline DICER1 pathogenic variant from either the maternal or paternal side)
b For pregnant women with a pathogenic germline DICER1 variant
c Transition to transvaginal ultrasound should be considered in older adolescents and adults when the ovaries are not visible with transabdominal 
ultrasound
*Based on expert consensus or majority decision but with inconsistent evidence or significant new evidence expected, except for annual neck 
palpation which is based on inconsistent evidence and limited expert agreement
**Based on inconsistent evidence and limited expert agreement
Minimum program* Extended program for consideration**
General surveillance Annual clinic review for symptoms and clinical 
examination where appropriate from birth to age 
20 years
Pulmonary surveillance US  3rd trimester of  pregnancya
Six-monthly chest X-ray from birth to age 6 years
Low-dose chest CT in first year and at age 2.5–3 years
Single chest X-ray at the time of diagnosis if DICER1 syn-
drome is diagnosed after age 6 years
Renal surveillance Six-monthly abdominal US from birth to age 6 years Single abdominal US at the time of diagnosis if DICER1 
syndrome is diagnosed after age 6 years
Thyroid surveillance Thyroid US every 3 years from age 8 to age 40 years
Annual neck palpation from age 8 to age 20  years**
Thyroid function monitoring during  pregnancyb
Thyroid US at the time of diagnosis if DICER1 syndrome is 
diagnosed between age 40 and age 50 years
Surveillance of the ovaries Annual US of the ovaries from age 8 to age 40  yearsc
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syndrome, surveillance should preferably be performed in 
a center with expertise. If this is not possible, we strongly 
advise clinicians to consult subspecialists with expertise in 
managing patients with DICER1 syndrome in case of sus-
picious physical examination or imaging findings. DICER1 
pathogenic variant carriers who have experienced a tumor 
may require additional surveillance of the organ that was 
affected. This needs to be discussed within a multidisci-
plinary team.
The upper and lower age limits for surveillance are 
based on the typical age of onset of DICER1-associated 
tumors, covering approximately 90–95% of reported cases 
[1, 3, 5, 12, 17, 23, 24], in accordance with practice regard-
ing other cancer predisposition syndromes, e.g. BRCA 
1/BRCA2-associated familial breast and ovarian cancer 
[25]. The extended program for consideration comprises 
additional surveillance procedures and recommendations 
for patients diagnosed with DICER1 syndrome outside 
Fig. 1  DICER1 syndrome 
patient information leaflet: 
possible signs and symptoms of 
DICER1-associated tumors
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the ages of the surveillance interval. These recommenda-
tions are based on inconsistent evidence and limited expert 
agreement. The extended program promotes personalized 
surveillance and shared decision making. How patients 
(or parents) perceive benefits and risks of surveillance can 
differ greatly between individuals [26–29]. Therefore, we 
encourage clinicians to thoroughly discuss potential ben-
efits and risks with patients (and/or parents). Patients have 
to be supported in choosing the surveillance program that 
best meets their needs.
Rationale for the recommendations
Pulmonary surveillance
PPB is one of the most important causes of DICER1-asso-
ciated morbidity and mortality [1, 12]. Clinically relevant 
PPBs are categorized into type I, II, or III. Type I PPB can 
progress to the more aggressive type II or III PPB if left 
untreated. The 5-year disease-free survival of type I PPB 
is significantly better than for type II and III PPB (79%, 
Fig. 1  (continued)
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59%, and 37%, respectively) [23]. These findings support 
the clinical utility of pulmonary imaging surveillance in 
DICER1 pathogenic variant carriers. It is important to note 
that type I PPB can also spontaneously regress to type Ir 
(regressed) PPB, which is identified with a substantial fre-
quency among adults with DICER1 syndrome and harbor 
little-to-no malignant potential, although, at present, there 
are no data regarding the proportion of progressing and 
regressing asymptomatic lung cysts [12].
Regular imaging with chest X-rays, followed by chest 
CT in cases with suspicious abnormalities on X-ray, is cur-
rently assumed to be the optimal surveillance method [30]. 
This approach balances the risk of radiation and possible 
need for sedation, against the risk of undetected disease. The 
classification of lung cysts on imaging determines whether 
subsequent follow-up by chest CT and/or surgery is needed 
[17]. Concerning features suggestive of PPB include pneu-
mothorax, the presence of more than one separate cystic 
pulmonary lesion, large unilocular cysts of over 2 cm diam-
eter, thick or irregularly septated cysts, pulmonary cysts not 
detected on antenatal ultrasound (c.f. cystic congenital pul-
monary airway malformation [CPAM]), and the presence 
of pleural effusion.
The SIOPE HGWG and CanGene-CanVar agree on cur-
rently used pulmonary surveillance imaging modalities, but 
advocate for modifying the age at which surveillance should 
stop. Current DICER1 syndrome surveillance protocols rec-
ommend chest X-rays every four to six months from birth to 
age 8 years, followed by annual chest X-rays until age 12 or 
age 18 years [15, 16]. Although type Ir PPB can present in 
individuals of any age, clinically significant PPB typically 
presents in infants and children [1, 12, 23]. The Interna-
tional Pleuropulmonary Blastoma registry reported clinical 
data from 350 PPB Cases [23]. Twenty-five percent of these 
cases (n = 89) were type I PPB, 7% (n = 26) were type Ir, and 
67% (n = 235) were type II or III PPB. The age by which 
95% of the cases of type I, type II, and type III or type II-III 
PPB were diagnosed was 2.5 years, 6.8 years and 5.3 years, 
respectively. These findings demonstrate that almost all clin-
ically relevant PPB cases present within the first six years of 
life. Accordingly, pulmonary surveillance at ages older than 
age 6 years, will provide marginal extra benefit, while the 
potential harm of overdiagnosis and excessive medicaliza-
tion increases. We therefore recommend six-monthly chest 
X-ray from birth to age 6 years. A single, baseline chest 
X-ray at the time of diagnosis can be considered in individu-
als diagnosed after age 6 years.
Another surveillance option for consideration is a low-
dose chest CT (without contrast) in the first year and at the 
age of 2.5–3 years, prior to the peak incidence of type II 
and III PPB [23]. This is in agreement with current sur-
veillance protocols for DICER1 pathogenic variant carri-
ers [15, 16]. The sensitivity of chest CT for detection of 
small pleuropulmonary blastoma cysts is superior to that 
of chest X-ray [30]. This potential benefit should, however, 
be carefully balanced against the potential risk of false-pos-
itive findings that may lead to unnecessary interventions, 
and against the risk of inducing cancer by ionizing radia-
tion exposure, particularly in children. Developing organs 
and tissues are more sensitive to the carcinogenic effects of 
ionizing radiation and the longer post-exposure life expec-
tancy in children increases the lifetime risk of developing 
radiation-induced cancer [31]. A further potential burden of 
CT scans in young children is the requirement for general 
anesthesia, although new CT scan techniques (e.g., ultrafast 
free breathing chest CT without anesthesia) and involvement 
of play-therapists may eliminate this burden [32]. Ongoing 
improvements on Magnetic Resonance Imaging (MRI) will 
potentially result in limited ionizing radiation exposure dur-
ing DICER1 syndrome surveillance in the future.
Renal surveillance
Renal tumors reported in individuals with DICER1 syn-
drome include cystic nephroma (CN), Wilms tumor and 
anaplastic sarcoma [1]. CN is one of the most common 
DICER1-associated tumors (estimated cumulative incidence 
among carriers of a germline DICER1 pathogenic variant 
[index and non-index case patients] is ~ 7% by the age of 
6 years), whereas malignant diseases as Wilms tumors and 
anaplastic sarcoma are very rare [12]. It has been suggested 
that renal anaplastic sarcoma evolves from CN [33, 34]. Ear-
lier diagnosis of CN may result in less extensive surgery and 
may prevent progression to renal anaplastic sarcoma.
To enable early detection of renal tumors, the SIOPE 
HGWG and CanGene-CanVar recommend six-monthly 
abdominal ultrasound from birth to 6 years of age. We 
propose stopping renal surveillance at a younger age than 
advised in current DICER1 syndrome surveillance proto-
cols [15, 16]. Given the rarity of Wilms tumors in DICER1 
pathogenic variant carriers, we adjusted the age and interval 
at which renal surveillance should be performed to the avail-
able data for CN which primarily affects children younger 
than 5 years of age [1, 12, 17].
Consideration should be given to a single, baseline 
abdominal ultrasound in individuals who are diagnosed with 
a pathogenic germline variant in DICER1 after the age of 
6. Even though the risks of developing a DICER-associated 
renal tumor after age 6 years is very low, two children with 
DICER1 syndrome were reported with CN after the age of 
10 years in the literature [12].
Thyroid surveillance
Multinodular goiter (MNG) is the most common DICER1 
syndrome associated condition, especially in women. 
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DICER1-associated MNG is usually diagnosed in the first 
decades of life [1]. Khan and colleagues calculated the 
cumulative incidence of either MNG diagnosis or thyroidec-
tomy (for MNG or thyroid nodules) in a family-based cohort 
study including 145 individuals with a germline DICER1 
pathogenic variant and 135 family controls [5]. The esti-
mated cumulative incidence of MNG or thyroidectomy by 
the age of 40 years was 75% in women (95% CI 59–89) 
and 17% in men (95% CI 7.3–35) with DICER1 syndrome. 
Thyroid disease can newly arise or pre-existing goiter can 
worsen during or shortly after pregnancy [35].
Thyroid cancer, especially differentiated thyroid can-
cer (DTC), has also been described in individuals with 
DICER1 syndrome, but the cumulative incidence is 
unknown [5, 12, 24, 36]. Khan and colleagues calculated 
that carriers of a germline DICER1 pathogenic variant 
have a 16-fold increased risk of developing DTC (95% 
CI 4.3–41) compared with the expected frequencies 
from the Surveillance, Epidemiology and End Results 
(SEER) Program [5]. To date, approximately 30 patients 
with (suspected) DICER1-associated thyroid cancer have 
been reported [24]. More than 90% of these patients were 
diagnosed with thyroid cancer before the age of 40 years, 
with a peak between age 10 and 20 years. The risk of 
DTC in carriers of a germline DICER1 pathogenic variant 
might be secondary to the greatly increased prevalence 
of benign thyroid nodules, although, given the low num-
ber of reported patients with DICER1-associated thyroid 
cancer, it has been suggested that only a small percentage 
of benign thyroid nodules progress to thyroid cancer [5, 
12, 24].
Neck palpation in combination with thyroid ultrasound 
has been recommended as surveillance modalities for 
DICER1 pathogenic variant carriers [15, 16, 37]. The sen-
sitivity to detect thyroid cancer is higher for ultrasound than 
for neck palpation, but this comes at the expense of lower 
specificity [38]. Even though no studies directly examined 
the harms associated with thyroid ultrasounds in individuals 
with DICER1 syndrome, overdiagnosis and overtreatment 
is a concern. Since DICER1 syndrome is characterized by a 
high prevalence of benign nodules [5], interpretation of thy-
roid ultrasound findings is challenging. The Thyroid Imag-
ing Reporting and Data Systems created by the American 
College of Radiology (ACR-TIRADS) and European Thy-
roid Association (EU-TIRADS) have not been validated in 
specific populations with a high prevalence of benign nodu-
lar thyroid disease, like individuals with DICER1 syndrome. 
Therefore, no recommendations for using this reporting sys-
tem can be made. Findings from a retrospective evaluation 
of clinical, molecular and histological data of ten patients 
with DICER1-associated DTCs, raises concern of unneces-
sary exposure of radioiodine treatment given the tumors’ low 
propensity for metastasis [24].
The great majority of DICER1-associated thyroid tumors 
reported to date behaved in an indolent manner [24]. Excep-
tions are clinically aggressive DICER1-mutated anaplastic 
thyroid carcinoma and childhood- and adolescent-onset 
poorly differentiated thyroid cancer (PDTC), although these 
tumors are rare [24, 36, 39]. Given the indolent nature of the 
great majority of DICER1-associated thyroid tumors, the 
SIOPE HGWG and CanGene-CanVar advise annual neck 
palpation from age 8 to age 20 years. In addition, patients 
need to be educated about possible symptoms of thyroid 
disease. In accordance with the recommendations of Schultz 
and colleagues [16], we advise thyroid ultrasound surveil-
lance to be initiated around age 8–11 years and not to be 
performed more than once every three years if the baseline 
ultrasound does not show any suspicious nodules. Additional 
ultrasounds are only indicated in the case of worrisome 
symptoms or ultrasound findings, such as gland asymmetry 
or lymphadenopathy. Since interpretation of thyroid ultra-
sound findings in the DICER1 syndrome population is chal-
lenging, thyroid surveillance should preferably be performed 
in a thyroid cancer expertise center. Suspicious findings need 
to be discussed within a multidisciplinary team with exper-
tise in managing patients with DICER1 syndrome.
Awareness for thyroid function monitoring is important 
during pregnancy in women who have undergone partial or 
complete thyroidectomy and in women with multinodular 
goiter in whom hyperthyroidism can develop [35].
Gynecological surveillance
DICER1-associated gynecological tumors include ovar-
ian sex cord-stromal tumors (especially Sertoli-Leydig cell 
tumor [SLCT], but also gynandroblastoma), cervical embry-
onal rhabdomyosarcoma (ERMS), and ovarian sarcomas [1, 
3, 35].The estimated cumulative incidence of ovarian SLCT 
in DICER1 syndrome patients (index and non-index case 
patients) is ~ 7% by the age of 60 years. Gynandroblastoma, 
cervical ERMS, and ovarian sarcomas are rare. To date, 
five gynandroblastomas, fourteen cervical ERMS and three 
ovarian sarcomas have been reported in individuals with 
germline pathogenic DICER1 variants [8, 35]. Stewart and 
colleagues performed Standardized Incidence Ratios (SIR) 
analysis of 102 nonproband DICER1 pathogenic variant 
carriers [12]. They calculated that DICER1 carriers have 
a markedly elevated risk of developing gynandroblastoma 
(SIR 1.0 ×  105)and SLCT (SIR 2.7 ×  103) compared with the 
expected frequencies from the SEER program.
SLCT can occur from early childhood to late adulthood, 
but ~ 95% of cases are diagnosed before 40 years of age, 
with a peak incidence between age 10 and 25 years [1, 3, 
12]. Well-differentiated stage I tumors are typically treated 
with surgery alone, whereas higher stages require adju-
vant chemotherapy [3]. Surveillance imaging might reduce 
344 J. J. Bakhuizen et al.
1 3
higher stage presentation and the need for adjuvant therapy, 
although the clinical efficacy has still to be determined. Girls 
and women with ovarian sex cord-stromal tumors often pre-
sent with symptoms of increased estrogen or androgen con-
centrations, including menstrual irregularity, virilization, 
and precocious puberty [3]. These symptoms can already be 
present in females with early stage tumors, triggering early 
diagnosis. In prepubertal girls visualization of the ovaries 
on transabdominal ultrasound is often challenging due to the 
small size of prepubertal ovaries [40]. There is no current 
evidence that early stage tumors can be detected with ultra-
sound before girls and women develop symptoms. Therefore, 
the SIOPE HGWG and CanGene-CanVar do not recommend 
standardized imaging of the ovaries but advise to primarily 
focus on clinical evaluation. Additional annual ultrasounds 
of the ovaries from age 8 to age 40 years can be consid-
ered on an individual basis and after a careful discussion of 
potential benefits and harms. One should not overestimate 
the value of an annual ultrasound to detect ovarian malig-
nancies as it may give a false sense of security. Perspectives 
on surveillance can differ between individuals and between 
countries due to different medical cultures. In some Euro-
pean countries, participation in preventive health check-ups, 
including ultrasounds of the ovaries, is quite common in the 
healthy population. We recommend annual broad clinical 
examination from birth to age 20 years for possible signs 
and symptoms of DICER1-associated tumors. Since the peak 
incidence of ovarian sex-cord stromal tumors exceeds the 
age of 20 years, continued education on proper vigilance 
for symptoms of these tumors are important, especially for 
women who do not choose ultrasound surveillance. The 
information leaflet can be used for this purpose.
In the coming years, (international) data collection will 
hopefully provide information elucidating whether ultra-
sound surveillance of the ovaries reduces morbidity by 
facilitating earlier diagnosis and treatment of as yet asymp-
tomatic individuals with DICER1-associated ovarian tumors.
Surveillance of the eyes
CBME in individuals with DICER1 syndrome is very rare, 
with an estimated cumulative incidence of 3% [10]. To date, 
approximately ten children with CBME and pathogenic ger-
mline DICER1 variants have been reported [10, 41–45]. The 
age of presentation varied between 3 and 16 years, with 90% 
of tumors manifesting in the first decade of life. Diagnostic 
delay is a common problem in patients with CBME. Most 
important causes of this diagnostic delay are initial misdi-
agnosis and mismanagement [46]. Almost half of reported 
CBME patients presented with secondary manifestations, 
like cataract, secondary glaucoma, and retrolental neoplastic 
cyclitic membrane [46, 47]. Some patients were treated for 
these conditions for a long time, or underwent surgery before 
recognition of the tumor [47].
Schultz and colleagues have recommended annual dilated 
ophthalmologic examination from 3 years of age through at 
least 10 years of age [16]. Dilated ophthalmologic examina-
tion may help detect CBME-associated signs, although the 
effect on morbidity and mortality is unclear. It is challenging 
to visualize a ciliary body tumor until enlargement causes 
secondary manifestations [46]. Therefore, it is unknown 
whether small, pre-symptomatic ciliary body tumors can 
be detected with a dilated ophthalmologic examination. In 
addition, dilated ophthalmologic examination can be very 
distressing for young children.
Given these difficulties, and the rarity of CBME in 
DICER1 pathogenic variant carriers, the SIOPE HGWG and 
CanGene-CanVar do not recommend standardized dilated 
ophthalmologic examination in asymptomatic carriers. We 
strongly recommend education of parents and guardians 
about possible CBME-associated signs and symptoms since 
awareness of these symptoms may prevent diagnostic delay.
Discussion
The recommendations of the SIOPE HGWG and CanGene-
CanVar, summarized in a surveillance protocol and a patient 
information leaflet, provide a framework for the surveillance 
management of DICER1 pathogenic variant carriers.
The simplified minimum surveillance program is intended 
to optimize the balance between benefits versus risks and 
burden, and to be practical. For example, equal surveillance 
intervals for different surveillance procedures should mini-
mize the number of hospital visits, and pulmonary and renal 
surveillance both stop at age 6, which is 6–12 years earlier 
than recommended by others [15, 16, 37].
Besides the value and utility of a simplified surveillance 
program, we want to highlight the importance of patient edu-
cation and shared decision making. Informing patients and 
families about (the limited knowledge of) age-related tumor 
risks, and potential benefits and harms of surveillance is fun-
damental to informed decision making. Studies have shown 
that effective information exchange between clinicians and 
(parents of) patients may change patients’ attitudes towards 
surveillance (e.g., acceptable risk threshold beliefs) and can 
enhance patients’ self-care skills [27, 48]. Our proposed sur-
veillance program for consideration provides a framework 
for a clinician-patient discussion about potential benefits and 
harms of surveillance. Further research is needed to validate 
the clinical utility of the proposed minimum and extended 
surveillance program and the information leaflet.
Aside from benign thyroid disease the penetrance of 
germline DICER1 pathogenic variants is generally low, but 
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some patients or families demonstrate significantly increased 
penetrance [1]. For example, individuals with mosaicism 
for DICER1 pathogenic missense variants in the RNase IIIb 
domain present with more severe DICER1-associated phe-
notypes, including higher tumor burden, earlier age of onset 
and greater range of phenotypes [49, 50]. To date, no other 
clear genotype–phenotype correlations have been identified 
and it is likely that genetic modifying factors contribute to 
phenotypic expression in carriers of a germline DICER1 
pathogenic variant [1]. Further research into the molecular 
characteristics of DICER1 syndrome is needed to improve 
our understanding of variable penetrance. Ultimately, it is 
hoped that patient-specific (epi)genetic factors can be taken 
into account when estimating DICER1-associated tumor 
risks and developing (personalized) surveillance proto-
cols. Until then, individuals with mosaicism for DICER1 
pathogenic missense variants in the RNase IIIb domain may 
require more intensive surveillance then proposed in this 
protocol.
In the context of developing cancer predisposition syn-
drome surveillance protocols, fundamental decisions have 
to be made, such as when to start and stop surveillance. 
One can choose surveillance programs that cover the mini-
mum and maximum reported age of onset of disease, or 
focus on the age period of highest risk—as we did—, and 
which is standard practice in better defined cancer pre-
disposition syndromes such as BRCA1/BRCA2-associated 
familial breast and ovarian cancer and Lynch syndrome. 
There is a fine balance between how much surveillance 
is “too much” versus “not enough” and we are aware that 
perspectives on surveillance can differ between countries 
due to different (medical) cultures and health insurance 
systems [51, 52]. Most European countries have a univer-
sal health care system, based on solidarity, equality and 
social responsibility, and funded through taxes (by public 
authorities) and/or social contributions (by employers and 
employees). In this context, critical evaluation of benefits 
and harms of surveillance is essential to justify the efforts 
and costs of surveillance. Although some may prefer more 
extensive surveillance programs, we feel that our simpli-
fied DICER1 syndrome surveillance protocol best reflects 
European perspectives on the impact of surveillance on 
daily life and its costs.
Progress has been made in the awareness of DICER1 syn-
drome, the associated tumors and ages of onset, although, 
as mentioned previously, many important research ques-
tions remain. Directions for future research are the natu-
ral history and growth rate of DICER1-associated tumors 
(especially lung cysts and thyroid nodules), the prevalence 
of adult tumors associated with DICER1 syndrome, and the 
clinical utility of proposed DICER1 syndrome surveillance 
protocols. Prospective data are needed to validate the clinical 
utility of proposed DICER1 syndrome surveillance protocols 
[15, 16, 37, 52]. The SIOPE HGWG and CanGene-CanVar 
strongly encourage enrollment of patients in the Interna-
tional Pleuropulmonary Blastoma (PPB)/DICER1 Registry 
(www. ppbre gistry. org) to expand the evidence base for sur-
veillance recommendations and to refine DICER1 syndrome 
penetrance. In Europe, research procedures must consider 
General Data Protection Regulation (GDPR) compliance. 
Patients may consider individual registration and/or national 
DICER1 registries can feed anonymized data into the Inter-
national PPB Registry where it could be analyzed and used 
to monitor the efficacy and patient tolerance of proposed 
surveillance protocols. To ensure ongoing optimization, we 
will reevaluate the proposed surveillance recommendations 
as new information becomes available.
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